Michael August Blazing, MD

Associate Professor of Medicine
Campus mail 7412HOSP North, Durham, NC 27710
Phone (919) 681-3945
Email address blazi001@mc.duke.edu

General focus: My research interests are in primary and secondary prevention of cardiovascular disease. Specifically, I am looking at compliance issues within the cardiology division and in the University as a whole with regard to evidence based treatment and secondary prevention of cardiovascular disease. I am using both retrospective and prospective collection of discharge data to try and analyze these trends. In the future, we hope to begin clinical trials with regard to various issues which are outstanding in primary and secondary prevention. Some of the issues include treatment of hypercholesterolemia in elderly patients, differences between the various statins with regard to affects on lipid profiles, and early treatment of hypercholesterolemia after MI.

As part of my work, I have served as a consultant with various drug companies with regard to focusing on active issues and treatment of hypercholesterolemia.

Key words: Primary prevention, secondary prevention, hyperlipidemia, homocysteine, and hypertension.

In Their Words

Education and Training

  • M.D., University of California, San Francisco, School of Medicine, 1987

Publications

Ambrosy, AP, Cerbin, LP, Fudim, M, Clare, RM, Lokhnygina, Y, Braunwald, E, Califf, RM, Cannon, CP, Tershakovec, AM, Roe, MT, and Blazing, MA. "Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status." The American Journal of Cardiology 122, no. 9 (November 2018): 1451-1458.

PMID
30180960
Full Text

Yang, S, Tsiatis, AA, and Blazing, M. "Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach." Biometrics 74, no. 3 (September 2018): 900-909.

PMID
29359317
Full Text

Simon, TG, Corey, KE, Cannon, CP, Blazing, M, Park, J-G, O'Donoghue, ML, Chung, RT, and Giugliano, RP. "The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe." International Journal of Cardiology (May 2018).

Full Text

Giugliano, RP, Cannon, CP, Blazing, MA, Nicolau, JC, Corbalán, R, Špinar, J, Park, J-G, White, JA, Bohula, EA, Braunwald, E, and IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators, . "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)." Circulation 137, no. 15 (April 2018): 1571-1582.

PMID
29263150
Full Text

Bohula, EA, Wiviott, SD, Giugliano, RP, Blazing, MA, Park, J-G, Murphy, SA, White, JA, Mach, F, Van de Werf, F, Dalby, AJ, White, HD, Tershakovec, AM, Cannon, CP, and Braunwald, E. "Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)." Circulation 136, no. 25 (December 2017): 2440-2450.

PMID
28972004
Full Text

Kato, ET, Cannon, CP, Blazing, MA, Bohula, E, Guneri, S, White, JA, Murphy, SA, Park, J-G, Braunwald, E, and Giugliano, RP. "Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)." Journal of the American Heart Association 6, no. 11 (November 18, 2017).

PMID
29151034
Full Text

Stanifer, JW, Charytan, DM, White, J, Lokhnygina, Y, Cannon, CP, Roe, MT, and Blazing, MA. "Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function." Journal of the American Society of Nephrology : Jasn 28, no. 10 (October 2017): 3034-3043.

PMID
28507057
Full Text

Fanaroff, AC, Roe, MT, Clare, RM, Lokhnygina, Y, Navar, AM, Giugliano, RP, Wiviott, SD, Tershakovec, AM, Braunwald, E, and Blazing, MA. "Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes." Journal of the American Heart Association 6, no. 9 (September 18, 2017).

PMID
28923989
Full Text

Pokharel, Y, Chinnakondepalli, K, Vilain, K, Wang, K, Mark, DB, Davies, G, Blazing, MA, Giugliano, RP, Braunwald, E, Cannon, CP, Cohen, DJ, and Magnuson, EA. "Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)." Circulation. Cardiovascular Quality and Outcomes 10, no. 5 (May 2017).

PMID
28506979
Full Text

Giugliano, RP, Wiviott, SD, Blazing, MA, De Ferrari, GM, Park, J-G, Murphy, SA, White, JA, Tershakovec, AM, Cannon, CP, and Braunwald, E. "Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial." Jama Cardiology 2, no. 5 (May 2017): 547-555.

PMID
28291866
Full Text

Pages